5 Minutes with Dr Louise Jackett
27 April 2016
To educate the next generation of melanoma researchers and doctors, MIA offers a number of unique clinical and research-based Fellowships each year. They are made possible thanks to the generosity of our donors.
Dr Louise Jackett is our 2016 Jani Haenke Melanoma Pathology Fellow.
Why did you apply for our Fellowship program?
I was drawn to the Melanoma Pathology Fellowship at MIA for the chance to work with a team at the forefront of melanoma research. Also, the diagnosis of melanoma and other melanocytic lesions under the microscope can be very difficult and this role allows me to learn from the best.
Tell us about your role with MIA?
I combine research activities and reporting of melanoma cases. Many of these cases are for patients treated at MIA but some are difficult cases that have come from pathologists nation-wide or internationally for expert opinion and I find these challenging and very interesting.
What drives you to come to work each day?
I find huge value in providing important information about patients’ health conditions. I also stay mindful of the generous donors who make my position possible.
Where did you work before coming to MIA?
I undertook my primary medical degree (MBBS, BMedSci) at the University of Tasmania and moved to Melbourne when I was a resident medical officer. There I pursued my anatomical pathology training over 5 years and recently gained fellowship with the Royal College of Pathologists of Australasia.
What are you hoping to achieve through your Fellowship at MIA?
I am hoping to increase my expertise in the tricky aspects of melanoma diagnosis, such as atypical melanocytic lesions and their distinction from melanoma. During the year I hope to publish on several projects that I am personally driving, as well as collaborating with many other MIA researchers by providing a pathological viewpoint and expertise.
What do you like to do in your spare time?
I like to counteract my sedentary microscope work by being very active! I love running, cycling and yoga.
SAVE THE DATE:
We want to thank every member of Team Melanoma and everyone who donated to them. With your help, we are moving closer to our goal of zero deaths from melanoma!
Lauren O'Brien tells us why she's running for a cause close to her heart
MIA could not do what we do without the incredible support and effort of our community fundraisers. We’d like to highlight some of the wonderful events organised by our community in
An international study, led by researchers from Melanoma Institute Australia, QIMR Berghofer Medical Research Institute and The University of Sydney as part of the Australian Melanoma Genome Project, has discovered that a drug traditionally used to treat a
Researchers from Melanoma Institute Australia took centre stage at the American Society of Clinical Oncology Annual Meeting in Chicago. Results presented by MIA’s contingent have the potential to create better patient outcomes and change the way advanced melanoma
Today is International Clinical Trials Day – a day to recognise and thank the amazing people who conduct, organise, and coordinate clinical trials.
“I’m the age Emma was when she passed away. It almost feels
As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions
As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions in support of the PBS listing.
MIA had four winners in the 2017 Premiers Awards. Find out how winning has influenced their work over the past year.
Cancer Council awards Melanoma Institute Australia researchers funding for ground-breaking cancer research projects
Almost $9 million of new funding was awarded to 13 ground-breaking cancer research projects at the 2019 Cancer Council NSW Research Awards.
Georgina V. Long is co-medical director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research. She is the first woman president of the Society for Melanoma Research.
Quintessential Aussie girl and media personality Sophie Monk has been announced as a National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.
Australian researchers have for the first time identified specific cells and receptors in the immune system which predict how a patient will respond to treatment with immunotherapies, potentially paving the way for the development of personalised therapy for all cancer patients.
Melanoma March is thrilled to introduce Ricky as our official Principal Partner for 2019!
World record holder, Olympian and Australian swimming champion Cate Campbell has been announced as National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.
MIA's expertise was essential to a recent Nature publication spearheaded by Perth’s Telethon Kids Institute and The University of Melbourne.
MIA is delighted to be hosting the MD Anderson pathologist on his first ever trip to Australia.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for dabrafenib and trametinib.